Collagen News and Research

Latest Collagen News and Research

Thymosin beta 4 improves neurological functional outcome after embolic stroke: Researchers

RegeneRx Biopharmaceuticals, Inc. today announced a research team from the Henry Ford Hospital in Detroit, MI, reported that Thymosin beta 4, administered to rats after embolic stroke, improved neurological functional outcome compared to control animals.

20 Jul 2010

Collagen Induction Therapy and Ultrasonic Microdermabrasion demonstrations at Lecada's open house

An open house on Thursday, June 17th, celebrated Lecada Medical Artistry's grand opening at 3710 West Azeele Street, Tampa. Lecada offers innovative treatments for face and body that provide aesthetic and anti-aging solutions designed to help you look and feel your best.

14 Jul 2010

New biological scaffolds will provide off-the-shelf tissue transplants

Professor John Fisher from The University of Leeds is speaking today (14 July) at the UK National Stem Cell Network Annual Science Meeting in Nottingham about his team's research into how biological scaffolding will pave the way for off- the-shelf tissue transplants.

14 Jul 2010

Innocoll submits SPA for phase 3 clinical trial of Cogenzia for adjuvant treatment of infected diabetic foot ulcers

Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Technologies Ltd., has submitted a Special Protocol Assessment (SPA) for a proposed phase 3 clinical trial to support the U.S. approval of Cogenzia™: Innocoll's topical antibiotic therapy for the adjuvant treatment of infected diabetic foot ulcers.

13 Jul 2010

Tips on skin care

Your skin protects you, heals itself and lasts a lifetime. Find how to give it some skin care in return, to help keep it looking and feeling its best.

12 Jul 2010

Pioneer Surgical Technology expands Biologics Product Specialist program

Pioneer Surgical Technology, Inc. recently expanded its Biologics Product Specialist program to provide sales and technical biologic expertise to support their growing line of products that address bone and soft tissue repair.

9 Jul 2010

Natrol offers two new beauty nutraceuticals that provide anti-aging skin and hair support for women

Most dermatologists would agree that premature skin aging can result from sun over-exposure, poor antioxidant intake, and excess free-radical production. Additionally, regarding hair health, about 20 million U.S. women experience premature hair-loss and hair-thinning. Natrol, Inc., a premier marketer, manufacturer, and distributor of nationally branded nutritional products, now offers two new beauty nutraceuticals that help provide anti-aging skin and hair support for women -- one dietary supplement helps optimize skin radiance via antioxidant protection for the skin, and another helps maximize follicular growth for hair.

9 Jul 2010

Integra LifeSciences launches DuraGen Plus Dural Regeneration Matrix - Spinal Matrix

Integra LifeSciences Holdings Corporation announced today the launch of DuraGen Plus® Dural Regeneration Matrix - Spinal Matrix, an absorbable and sutureless collagen onlay indicated as a dura substitute for the repair of dura mater.

9 Jul 2010

Fibrocell Science completes enrollment in azficel-T histology study

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currently under review by the U.S. Food and Drug Administration for the treatment of moderate to severe nasolabial fold wrinkles.

8 Jul 2010

Wound Care Innovations signs distribution agreement with KOMED for CellerateRx

Wound Management Technologies, Inc. announced an important milestone in its planned growth strategy. Its wholly owned subsidiary Wound Care Innovations signed a distribution agreement with KOMED, LLC of Georgia for direct response advertising on television and niche online marketing of CellerateRx® in the United States.

1 Jul 2010

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

30 Jun 2010

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style. As in the other types of chronic hepatitis, collagen fibers continuously accumulate in the liver through the course of NASH toward cirrhosis and hepatocellular carcinoma development.

29 Jun 2010

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced results of preclinical studies demonstrating that its clinical candidate, AVL-292, potently inhibits B cell receptor signaling, and demonstrates efficacy in a rodent model of rheumatoid arthritis. These new data were presented Saturday, June 26, 2010 at the Federation of Clinical Immunology Societies (FOCIS) 2010 annual meeting in Boston, MA.

29 Jun 2010

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs' Steering Committee's top choice to take to trial and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX. The first case to reach a verdict, Maley v. Merck, resulted in a defense verdict for Merck on May 5, 2010.

28 Jun 2010

Kensey Nash announces strategic agreement with Arthrex for ECM technology

Kensey Nash Corporation, a regenerative medicine company, and Arthrex, Inc., a worldwide leader in sports medicine product development and educational services for orthopaedic surgeons, today announced a strategic agreement regarding products developed from Kensey Nash's unique extracellular matrix technology.

24 Jun 2010

Kensey Nash, St. Jude Medical sign two-year Supply Agreement

Kensey Nash Corporation, a regenerative medicine company, today announced that it entered into a new two-year Supply Agreement with St. Jude Medical, Inc. for the period from January 1, 2011 to December 31, 2012. The agreement provides for Kensey Nash to be the exclusive outside supplier of collagen plugs, one of the key resorbable components of the Angio-Seal Vascular Closure Device, the leading arterial puncture closure product in the world.

24 Jun 2010

Scientists discover septet of overactive genes that control bodily function

In what is believed to be the largest review of the human genetic code to determine why some people's blood platelets are more likely to clump faster than others, scientists at Johns Hopkins and in Boston have found a septet of overactive genes, which they say likely control that bodily function.

23 Jun 2010

Studying cells in 3-D could help develop drugs to prevent cancer from spreading: Researchers

Showing movies in 3-D has produced a box-office bonanza in recent months. Could viewing cell behavior in three dimensions lead to important advances in cancer research? A new study led by Johns Hopkins University engineers indicates it may happen. Looking at cells in 3-D, the team members concluded, yields more accurate information that could help develop drugs to prevent cancer's spread.

22 Jun 2010

E'shee Clinical Esthetic introduces revolutionary new products for skin care

E'shee Skin Care products are the result of a careful collaboration of skin care professionals, doctors and chemists; these revolutionary new products are the next step in skin care.

19 Jun 2010

VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 possesses anti-inflammatory properties and effectively reduced the symptoms of arthritis in experimental models.

17 Jun 2010

Collagen News and Research

Latest Collagen News and Research

Thymosin beta 4 improves neurological functional outcome after embolic stroke: Researchers

Collagen Induction Therapy and Ultrasonic Microdermabrasion demonstrations at Lecada's open house

New biological scaffolds will provide off-the-shelf tissue transplants

Innocoll submits SPA for phase 3 clinical trial of Cogenzia for adjuvant treatment of infected diabetic foot ulcers

Tips on skin care

Pioneer Surgical Technology expands Biologics Product Specialist program

Natrol offers two new beauty nutraceuticals that provide anti-aging skin and hair support for women

Integra LifeSciences launches DuraGen Plus Dural Regeneration Matrix - Spinal Matrix

Fibrocell Science completes enrollment in azficel-T histology study

Wound Care Innovations signs distribution agreement with KOMED for CellerateRx

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Merck challenges New York jury decision in federal FOSAMAX retrial

Kensey Nash announces strategic agreement with Arthrex for ECM technology

Kensey Nash, St. Jude Medical sign two-year Supply Agreement

Scientists discover septet of overactive genes that control bodily function

Studying cells in 3-D could help develop drugs to prevent cancer from spreading: Researchers

E'shee Clinical Esthetic introduces revolutionary new products for skin care

VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Collagen News and Research

Latest Collagen News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in